85 related articles for article (PubMed ID: 10629645)
41. Neutrophil activation, vascular leak toxicity, and cytolysis during interleukin-2 infusion in human cancer.
Carey PD; Wakefield CH; Guillou PJ
Surgery; 1997 Nov; 122(5):918-26. PubMed ID: 9369892
[TBL] [Abstract][Full Text] [Related]
42. Regulation of bcl-2 and fas expression in primary activation of human peripheral lymphocytes is not sensitive to dexamethasone or cyclosporin-A.
Sfikakis PP; Souliotis VL; Akbar AN; Katsilambros N; Hoffbrand VA; Panayiotidis P
Hum Immunol; 1996 Oct; 50(2):121-6. PubMed ID: 8891735
[TBL] [Abstract][Full Text] [Related]
43. Correlation between the expression of Fas, Bcl-2 in peripheral blood lymphocytes and the level of IFN-gamma, IL-4 in serum of patients with condyloma acuminata.
Liu H; Lin N; Tu Y; Liu Z; Huang C
J Huazhong Univ Sci Technolog Med Sci; 2004; 24(1):90-1. PubMed ID: 15165126
[TBL] [Abstract][Full Text] [Related]
44. Effect of IFN-γ and IL-4 levels on the expression of Fas and Bcl-2 in peripheral blood lymphocytes in hemodialysis patients.
Li D; Meng J; Yu N; Jia F; Sun X; Zhang A; Wang S; Gao F; Jing Y
J Artif Organs; 2011 Jun; 14(2):120-4. PubMed ID: 21534013
[TBL] [Abstract][Full Text] [Related]
45. [Roncoleukin immunomodulation in pulmonary tuberculosis].
Knoring BE; El'kin AV; Smirnov MN; Sakharova IIa; Basek TS
Probl Tuberk; 1999; (5):26-9. PubMed ID: 10565213
[TBL] [Abstract][Full Text] [Related]
46. Effect of endogenous interleukin-6 on Fas (APO-1/CD95) receptor expression in advanced melanoma patients.
Mouawad R; Antoine EC; Khayat D; Soubrane C
Cytokines Cell Mol Ther; 2000 Sep; 6(3):135-40. PubMed ID: 11140882
[TBL] [Abstract][Full Text] [Related]
47. Neopterin, soluble IL-2 receptor and IL-6 secretion during IL-2 cancer immunotherapy: prognostic significance in relation to IL-12 variations.
Lissoni P; Barni S; Di Felice G; Majorca F; Fumagalli L
Int J Biol Markers; 1997; 12(3):134-6. PubMed ID: 9479598
[No Abstract] [Full Text] [Related]
48. Defective Fas ligand production in lymphocytes from MS patients.
Macchi B; Matteucci C; Nocentini U; Tacconi S; Pagnini V; Mastino A; Caltagirone C
Neuroreport; 2001 Dec; 12(18):4113-6. PubMed ID: 11742248
[TBL] [Abstract][Full Text] [Related]
49. [Disturbance of apoptosis of peripheral blood lymphocytes in different variants of bronchial asthma].
Mineev VN; Trofimov VI; Nesterovich II; Emanuél' VL; Lugovaia AV
Ter Arkh; 2008; 80(3):43-9. PubMed ID: 18441683
[TBL] [Abstract][Full Text] [Related]
50. Photopheresis treatment enhances CD95 (fas) expression in circulating lymphocytes of patients with systemic sclerosis and induces apoptosis.
Aringer M; Graninger WB; Smolen JS; Kiener HP; Steiner CW; Trautinger F; Knobler R
Br J Rheumatol; 1997 Dec; 36(12):1276-82. PubMed ID: 9448588
[TBL] [Abstract][Full Text] [Related]
51. [Content of the antigenic determinants CD16, CD25, CD95, and HLA-DR in induced sputum of patients with bronchial asthma and chronic obstructive bronchitis].
Nevzorova VA; Konovalova EN; Pazych SA; Kostiushko AV
Ter Arkh; 2003; 75(11):61-4. PubMed ID: 14708445
[TBL] [Abstract][Full Text] [Related]
52. Age-related changes of apoptotic cell death in human lymphocytes.
Schindowski K; Leutner S; Müller WE; Eckert A
Neurobiol Aging; 2000; 21(5):661-70. PubMed ID: 11016535
[TBL] [Abstract][Full Text] [Related]
53. [Expression and significance of Fas/APO-1 and Bcl-2 protein in human lung cancer.].
Yi Y; Gan X; Lin C; Hu X
Zhongguo Fei Ai Za Zhi; 1999 Mar; 2(1):17-9. PubMed ID: 20880468
[TBL] [Abstract][Full Text] [Related]
54. Neurological ischemic attack and interleukin-2 therapy.
Donnet A; Tubiana N; Chinot O; Juin P
Stroke; 1991 Jun; 22(6):819-20. PubMed ID: 2057986
[No Abstract] [Full Text] [Related]
55. Recombinant interleukin 2 adjunctive therapy in multidrug-resistant tuberculosis.
Johnson B; Bekker LG; Ress S; Kaplan G
Novartis Found Symp; 1998; 217():99-106; discussion 106-11. PubMed ID: 9949803
[TBL] [Abstract][Full Text] [Related]
56. [Inhibition of interleukin-2-dependent proliferation of human lymphocytes and expression of interleukin-2 receptors by synthetic peptides--fragments of alpha-2 interferon].
Danilkovich AV; Freze KV; Targoni OS; Karulin AIu; Sheval'e AF; Gusev MV; Sukhikh GT
Biull Eksp Biol Med; 1994 Jan; 117(1):65-8. PubMed ID: 8193336
[No Abstract] [Full Text] [Related]
57. Stimulatory and protective effects of alkylating agents applied in ultra-low concentrations.
Pukhalsky AL; Shmarina GV
Pharmacology; 2001; 62(3):129-32. PubMed ID: 11287812
[TBL] [Abstract][Full Text] [Related]
58. Can expression of CD95 (Fas/APO-1) ligand on grafts or tumor cells prevent their rejection?
Allison J; Seino K; Yagita H
Springer Semin Immunopathol; 1998; 19(3):311-22. PubMed ID: 9540159
[No Abstract] [Full Text] [Related]
59. CD95-ligand (Fas-L)-expressing epidermal lymphocytes.
De Panfilis G; Marcelli M; Pasolini G; Torresani C
Br J Dermatol; 2000 Oct; 143(4):892-3. PubMed ID: 11069480
[No Abstract] [Full Text] [Related]
60. [Immunologic tumor therapy].
Krankenpfl J; 1993 Sep; 31(9):370-1. PubMed ID: 8411959
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
